These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 23206402)

  • 1. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
    Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
    Seo KW; Kim SH; Park J; Son Y; Yoo HS; Lee KY; Jang YS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):102-12. PubMed ID: 23200821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA.
    Shin SJ; Bae JL; Cho YW; Lee DY; Kim DH; Yang MS; Jang YS; Yoo HS
    FEMS Immunol Med Microbiol; 2005 Feb; 43(2):155-64. PubMed ID: 15681145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
    Chiang CH; Huang WF; Huang LP; Lin SF; Yang WJ
    Vaccine; 2009 Jul; 27(34):4565-70. PubMed ID: 19520199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
    Xu F; Chen X; Shi A; Yang B; Wang J; Li Y; Guo X; Blackall PJ; Yang H
    Vet Microbiol; 2006 Dec; 118(3-4):230-9. PubMed ID: 16930871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral immunization of mice with Saccharomyces cerevisiae expressing a neutralizing epitope of ApxIIA exotoxin from Actinobacillus pleuropneumoniae induces systemic and mucosal immune responses.
    Shin MK; Lee WJ; Jung MH; Cha SB; Shin SW; Yoo A; Kim DH; Yoo HS
    Microbiol Immunol; 2013 Jun; 57(6):417-25. PubMed ID: 23773020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
    Liu J; Chen Y; Hu L; Bei W; Chen H
    Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):305-10. PubMed ID: 20518341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge.
    Lu YC; Li MC; Chen YM; Chu CY; Lin SF; Yang WJ
    Vaccine; 2011 Oct; 29(44):7740-6. PubMed ID: 21835218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria.
    Lee KY; Kim DH; Kang TJ; Kim J; Chung GH; Yoo HS; Arntzen CJ; Yang MS; Jang YS
    FEMS Immunol Med Microbiol; 2006 Dec; 48(3):381-9. PubMed ID: 17054716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice.
    Shin SJ; Shin SW; Kang ML; Lee DY; Yang MS; Jang YS; Yoo HS
    J Vet Sci; 2007 Dec; 8(4):383-92. PubMed ID: 17993753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs.
    Wu HC; Yeh PH; Hsueh KJ; Yang WJ; Chu CY
    J Appl Microbiol; 2018 Jun; 124(6):1366-1376. PubMed ID: 29431246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
    Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
    Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia.
    Haga Y; Ogino S; Ohashi S; Ajito T; Hashimoto K; Sawada T
    J Vet Med Sci; 1997 Feb; 59(2):115-20. PubMed ID: 9070983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
    Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
    Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.
    Loera-Muro A; Angulo C
    Vet Microbiol; 2018 Apr; 217():66-75. PubMed ID: 29615259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral immunization against porcine pleuropneumonia using the cubic phase of monoolein and purified toxins of Actinobacillus pleuropneumoniae.
    Lopez-Bermudez J; Quintanar-Guerrero D; Lara Puente H; Tórtora Perez J; Suárez Güemez F; Ciprián Carrasco A; Mendoza Elvira S
    Vaccine; 2014 Nov; 32(50):6805-11. PubMed ID: 25446832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.
    Wang C; Wang Y; Shao M; Si W; Liu H; Chang Y; Peng W; Kong X; Liu S
    Vaccine; 2009 Sep; 27(42):5816-21. PubMed ID: 19654060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
    Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
    Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.
    Liu J; Chen X; Lin L; Tan C; Chen Y; Guo Y; Jin M; Guo A; Bei W; Chen H
    Vaccine; 2007 Nov; 25(44):7696-705. PubMed ID: 17767980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model.
    Park J; Seo KW; Kim SH; Lee HY; Kim B; Lim CW; Kim JH; Yoo HS; Jang YS
    Vet Microbiol; 2015 May; 177(1-2):142-53. PubMed ID: 25818577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.